Cargando…
Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA(2)), UCM-14216, Ameliorates Spinal Cord Injury in Mice
[Image: see text] Spinal cord injuries (SCIs) irreversibly disrupt spinal connectivity, leading to permanent neurological disabilities. Current medical treatments for reducing the secondary damage that follows the initial injury are limited to surgical decompression and anti-inflammatory drugs, so t...
Autores principales: | Khiar-Fernández, Nora, Zian, Debora, Vázquez-Villa, Henar, Martínez, R. Fernando, Escobar-Peña, Andrea, Foronda-Sainz, Román, Ray, Manisha, Puigdomenech-Poch, Maria, Cincilla, Giovanni, Sánchez-Martínez, Melchor, Kihara, Yasuyuki, Chun, Jerold, López-Vales, Rubèn, López-Rodríguez, María L., Ortega-Gutiérrez, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421655/ https://www.ncbi.nlm.nih.gov/pubmed/35948083 http://dx.doi.org/10.1021/acs.jmedchem.2c00046 |
Ejemplares similares
-
Dual Role of Lysophosphatidic Acid Receptor 2 (LPA(2)) in Amyotrophic Lateral Sclerosis
por: Puigdomenech-Poch, Maria, et al.
Publicado: (2021) -
Phosphorylation and Internalization of Lysophosphatidic Acid Receptors LPA(1), LPA(2), and LPA(3)
por: Alcántara-Hernández, Rocío, et al.
Publicado: (2015) -
Lysophosphatidic acid (LPA)-antibody (504B3) engagement detected by interferometry identifies off-target binding
por: Ray, Manisha, et al.
Publicado: (2021) -
2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306),
an Orally Bioavailable Positive Allosteric Modulator of the Human
Dopamine D(1) Receptor for Parkinson’s Disease
por: García-Cárceles, Javier, et al.
Publicado: (2022) -
Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain
por: Inoue, Makoto, et al.
Publicado: (2008)